世界の内分泌癌治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neuroendocrine Carcinoma Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4566 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、内分泌癌治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ソマトスタチン類似体、標的療法、化学療法）、用途別市場規模（病院、クリニック、オンコロジーセンター、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・内分泌癌治療の市場動向 ・企業の競争状況、市場シェア ・内分泌癌治療の種類別市場規模と予測2016-2027（ソマトスタチン類似体、標的療法、化学療法） ・内分泌癌治療の用途別市場規模と予測2016-2027（病院、クリニック、オンコロジーセンター、外来手術センター、その他） ・内分泌癌治療の北米市場規模2016-2027（アメリカ、カナダ） ・内分泌癌治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・内分泌癌治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・内分泌癌治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・内分泌癌治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Novartis、Chiasma, Inc.、Ipsen、AbbVie、Bausch Health、Jubilant、Teva Pharmaceutical Industries Ltd.、Roche、Mateon） ・結論

Market Analysis and Insights: Global Neuroendocrine Carcinoma Treatment Market
The global Neuroendocrine Carcinoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuroendocrine Carcinoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuroendocrine Carcinoma Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuroendocrine Carcinoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuroendocrine Carcinoma Treatment market.

Global Neuroendocrine Carcinoma Treatment Scope and Market Size
Neuroendocrine Carcinoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Somatostatin Analogs
Targeted Therapy
Chemotherapy

Segment by Application
Hospitals
Clinics
Oncology Centers
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Novartis
Chiasma, Inc.
Ipsen
AbbVie
Bausch Health
Jubilant
Teva Pharmaceutical Industries Ltd.
Roche
Mateon

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Somatostatin Analogs
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Oncology Centers
1.3.5 Ambulatory Surgical Centers
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Treatment Market Perspective (2016-2027)
2.2 Neuroendocrine Carcinoma Treatment Growth Trends by Regions
2.2.1 Neuroendocrine Carcinoma Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuroendocrine Carcinoma Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Neuroendocrine Carcinoma Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Neuroendocrine Carcinoma Treatment Industry Dynamic
2.3.1 Neuroendocrine Carcinoma Treatment Market Trends
2.3.2 Neuroendocrine Carcinoma Treatment Market Drivers
2.3.3 Neuroendocrine Carcinoma Treatment Market Challenges
2.3.4 Neuroendocrine Carcinoma Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue (2016-2021)
3.1.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Neuroendocrine Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Treatment Revenue
3.4 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Treatment Revenue in 2020
3.5 Neuroendocrine Carcinoma Treatment Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Carcinoma Treatment Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Type (2016-2021)
4.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2022-2027)

5 Neuroendocrine Carcinoma Treatment Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Application (2016-2021)
5.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neuroendocrine Carcinoma Treatment Market Size (2016-2027)
6.2 North America Neuroendocrine Carcinoma Treatment Market Size by Type
6.2.1 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021)
6.2.2 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027)
6.2.3 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2027)
6.3 North America Neuroendocrine Carcinoma Treatment Market Size by Application
6.3.1 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021)
6.3.2 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027)
6.3.3 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2027)
6.4 North America Neuroendocrine Carcinoma Treatment Market Size by Country
6.4.1 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021)
6.4.2 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neuroendocrine Carcinoma Treatment Market Size (2016-2027)
7.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Type
7.2.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021)
7.2.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027)
7.2.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2027)
7.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Application
7.3.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021)
7.3.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027)
7.3.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2027)
7.4 Europe Neuroendocrine Carcinoma Treatment Market Size by Country
7.4.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021)
7.4.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size (2016-2027)
8.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type
8.2.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application
8.3.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region
8.4.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Treatment Market Size (2016-2027)
9.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type
9.2.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2027)
9.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application
9.3.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2027)
9.4 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country
9.4.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size (2016-2027)
10.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type
10.2.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application
10.3.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country
10.4.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Treatment Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Treatment Introduction
11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Chiasma, Inc.
11.3.1 Chiasma, Inc. Company Details
11.3.2 Chiasma, Inc. Business Overview
11.3.3 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Introduction
11.3.4 Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.3.5 Chiasma, Inc. Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Details
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Treatment Introduction
11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.4.5 Ipsen Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Neuroendocrine Carcinoma Treatment Introduction
11.5.4 AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.5.5 AbbVie Recent Development
11.6 Bausch Health
11.6.1 Bausch Health Company Details
11.6.2 Bausch Health Business Overview
11.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Introduction
11.6.4 Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.6.5 Bausch Health Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Details
11.7.2 Jubilant Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Treatment Introduction
11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.7.5 Jubilant Recent Development
11.8 Teva Pharmaceutical Industries Ltd.
11.8.1 Teva Pharmaceutical Industries Ltd. Company Details
11.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.8.3 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Introduction
11.8.4 Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.8.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Neuroendocrine Carcinoma Treatment Introduction
11.9.4 Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.9.5 Roche Recent Development
11.10 Mateon
11.10.1 Mateon Company Details
11.10.2 Mateon Business Overview
11.10.3 Mateon Neuroendocrine Carcinoma Treatment Introduction
11.10.4 Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021)
11.10.5 Mateon Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Somatostatin Analogs
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Global Neuroendocrine Carcinoma Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neuroendocrine Carcinoma Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuroendocrine Carcinoma Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2016-2021)
Table 9. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2022-2027)
Table 11. Neuroendocrine Carcinoma Treatment Market Trends
Table 12. Neuroendocrine Carcinoma Treatment Market Drivers
Table 13. Neuroendocrine Carcinoma Treatment Market Challenges
Table 14. Neuroendocrine Carcinoma Treatment Market Restraints
Table 15. Global Neuroendocrine Carcinoma Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neuroendocrine Carcinoma Treatment Market Share by Players (2016-2021)
Table 17. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2020)
Table 18. Ranking of Global Top Neuroendocrine Carcinoma Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service
Table 22. Date of Enter into Neuroendocrine Carcinoma Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neuroendocrine Carcinoma Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Neuroendocrine Carcinoma Treatment Product
Table 65. Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Neuroendocrine Carcinoma Treatment Product
Table 70. Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Chiasma, Inc. Company Details
Table 73. Chiasma, Inc. Business Overview
Table 74. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Product
Table 75. Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 76. Chiasma, Inc. Recent Development
Table 77. Ipsen Company Details
Table 78. Ipsen Business Overview
Table 79. Ipsen Neuroendocrine Carcinoma Treatment Product
Table 80. Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 81. Ipsen Recent Development
Table 82. AbbVie Company Details
Table 83. AbbVie Business Overview
Table 84. AbbVie Neuroendocrine Carcinoma Treatment Product
Table 85. AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 86. AbbVie Recent Development
Table 87. Bausch Health Company Details
Table 88. Bausch Health Business Overview
Table 89. Bausch Health Neuroendocrine Carcinoma Treatment Product
Table 90. Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 91. Bausch Health Recent Development
Table 92. Jubilant Company Details
Table 93. Jubilant Business Overview
Table 94. Jubilant Neuroendocrine Carcinoma Treatment Product
Table 95. Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 96. Jubilant Recent Development
Table 97. Teva Pharmaceutical Industries Ltd. Company Details
Table 98. Teva Pharmaceutical Industries Ltd. Business Overview
Table 99. Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 100. Teva Pharmaceutical Industries Ltd. Recent Development
Table 101. Roche Company Details
Table 102. Roche Business Overview
Table 103. Roche Neuroendocrine Carcinoma Treatment Product
Table 104. Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 105. Roche Recent Development
Table 106. Mateon Company Details
Table 107. Mateon Business Overview
Table 108. Mateon Neuroendocrine Carcinoma Treatment Product
Table 109. Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2016-2021) & (US$ Million)
Table 110. Mateon Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Treatment Market Share by Type: 2020 VS 2027
Figure 2. Somatostatin Analogs Features
Figure 3. Targeted Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Oncology Centers Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Others Case Studies
Figure 11. Neuroendocrine Carcinoma Treatment Report Years Considered
Figure 12. Global Neuroendocrine Carcinoma Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Neuroendocrine Carcinoma Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Neuroendocrine Carcinoma Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2022-2027)
Figure 16. Global Neuroendocrine Carcinoma Treatment Market Share by Players in 2020
Figure 17. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2020
Figure 19. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Neuroendocrine Carcinoma Treatment Market Share by Type (2016-2027)
Figure 23. North America Neuroendocrine Carcinoma Treatment Market Share by Application (2016-2027)
Figure 24. North America Neuroendocrine Carcinoma Treatment Market Share by Country (2016-2027)
Figure 25. United States Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Neuroendocrine Carcinoma Treatment Market Share by Type (2016-2027)
Figure 29. Europe Neuroendocrine Carcinoma Treatment Market Share by Application (2016-2027)
Figure 30. Europe Neuroendocrine Carcinoma Treatment Market Share by Country (2016-2027)
Figure 31. Germany Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Region (2016-2027)
Figure 41. China Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Neuroendocrine Carcinoma Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Neuroendocrine Carcinoma Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Neuroendocrine Carcinoma Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 61. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 62. Chiasma, Inc. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 63. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 64. AbbVie Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 65. Bausch Health Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 66. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 67. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 68. Roche Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 69. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---